Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 247-825-4 | CAS number: 26586-02-7
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1969, April through June; different groups of animals were dosed between 2009-04-30 and 2009-05-29
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Acceptable study, briefly documented; pre-GLP study.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 969
- Report date:
- 1969
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Principles of method if other than guideline:
- BASF-Test (BASF internal method). In principle, the methods described by OECD TG 401 are used.
- GLP compliance:
- no
- Remarks:
- pre-GLP study
- Test type:
- standard acute method
- Limit test:
- no
Test material
- Reference substance name:
- (E)-3-formylbut-2-enyl acetate
- EC Number:
- 247-825-4
- EC Name:
- (E)-3-formylbut-2-enyl acetate
- Cas Number:
- 26586-02-7
- Molecular formula:
- C7H10O3
- IUPAC Name:
- (2E)-3-methyl-4-oxobut-2-en-1-yl acetate
- Details on test material:
- - Name of test material (as cited in study report): beta-formylcrotyl-acetate (trans-3-formyl-buten-2-ol-1-acetate), synthesized by rearrangement reaction
- Physical state: liquid
- Analytical purity: 94%
- Impurities (identity and concentrations): no data
No further data
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: Gassner
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
male and female Gassner rats
- Weight at study initiation: body weight range: 170 - 285 g (males); 160 - 200 g (females)
No further data
ENVIRONMENTAL CONDITIONS: no data
IN-LIFE DATES: no data
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: aqueous Traganth
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 2, 4, 8, 20 % (v/v)
MAXIMUM DOSE VOLUME APPLIED: 2500 ml/kg bw; see freetext - Doses:
- ca. 212, 424, 848, 1060, 1326, 1700, 2120, 2650 mg/kg bw (200, 400, 800, 1000, 1250, 1600, 2000, 2500 ml/kg bw); see freetext
- No. of animals per sex per dose:
- 10/sex/dose
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 7 days
- Necropsy of survivors performed: yes/no
- Other examinations performed: clinical signs, body weight, gross pathology
Results and discussion
Effect levels
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- ca. 1 430 mg/kg bw
- Remarks on result:
- other: Original value: approximate median lethal dose (ALD): ca. 1350 mm³/kg bw (ca. 1430 mg/kg bw; calculated with a density of 1.0605 g/ml).
- Mortality:
- At 7 days post dose, mortality was 0/20, 0/20, 0/20, 2/20, 8/20, 14/20, 20/20, and 20/20 in the groups given 200, 400, 800, 1000, 1250, 1600, 2000, and 2500 ml/kg, respectively. All deaths occurred within the first 2 days post dose. No lethality was observed within the first hour after dosing.
- Clinical signs:
- other: 2500 - 1600 ml/kg: dyspnea, intermittent respiration, serous secretion of the buccal cavity, twitching, indication of rolling fits, piloerection, high-legged gait, squatting posture, shallow respiration, apathy, adhesions at the eyes, and ruffled fur. The
- Gross pathology:
- Examination of decedents:
smears at nostrils and anus, distended gastro-intestinal tract, fluid-enriched serous membranes (especially of the thorax), serous content of the stomach and putrefaction.
Examination of survivors:
adhesive-phlogistic processes in the gastric wall (possibly due to dosing by gavage).
Any other information on results incl. tables
Table: mortality data
Group |
Dose level |
Mortality rate after |
||||
[ml/kg bw] |
[mg/kg bw] |
1 h |
24 h |
48 h |
7 d |
|
1 |
2500 |
ca. 2650 |
0/20 |
20/20 |
20/20 |
20/20 |
2 |
2000 |
ca. 2120 |
0/20 |
20/20 |
20/20 |
20/20 |
3 |
1600 |
ca. 1700 |
0/20 |
14/20 |
14/20 |
14/20 |
4 |
1250 |
ca. 1326 |
0/20 |
7/20 |
8/20 |
8/20 |
5 |
1000 |
ca. 1060 |
0/20 |
2/20 |
2/20 |
2/20 |
6 |
800 |
ca. 848 |
0/20 |
0/20 |
0/20 |
0/20 |
7 |
400 |
ca. 424 |
0/20 |
0/20 |
0/20 |
0/20 |
8 |
200 |
ca. 212 |
0/20 |
0/20 |
0/20 |
0/20 |
Applicant's summary and conclusion
- Interpretation of results:
- Category 4 based on GHS criteria
- Remarks:
- Migrated information: harmful if swallowed
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
